Please assess the completion status of the following clinical trial:

Trial Title: Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA \>= 10\^3 IU/ml at screening~* Chronic HCV infection, defined as positive HCV antibody and/or HCV RNA more than 6 months prior to screening~* HCV Genotype 1, 2, 3, 4, 5 or 6~* Otherwise eligible for lung transplant at study site~Exclusion Criteria:~* Age \<18~* Treatment with any of the following agents:~  * Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 SOF/VEL~ * Carbamazepine, phenytoin, phenobarbital, oxcarbazepine~ * Rifabutin, rifampin or rifapentine~ * HIV regimens containing tenofovir or tipranavir/ritonavir~ * St John's wort~ * PPIs, including: Omeprazole, pantoprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole~ * Modafinil~* Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance~* Hepatitis B surface antigen positive~* History of hepatic encephalopathy or variceal hemorrhage~* Abnormal hematological and biochemical parameters, including:~  * Hemoglobin \<8g/dL~ * Platelets \<= 50,000/mm\^3~ * ALT (alanine aminotransferase), AST (aspartase aminotransferase) or alkaline phosphatase \>=10 times ULN~ * Total bilirubin \>3mg/dL~ * Severe renal impairment, ie creatinine clearance (CrCl) \<30mL/min~* Pregnant women or women planning to become pregnant~* Women or are breastfeeding~* Active or recent history (\<=1 year) of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epclusa (Type: OTHER): Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.

Based on this trial design, predict the completion outcome and termination type (if applicable).